Regeneron Seeks FDA Approval of VEGF Trap-Eye for Wet AMD
As expected, Regeneron Pharmaceuticals Inc. submitted a biologics license application (BLA) to the FDA for its VEGF Trap-Eye (aflibercept ophthalmic solution) to treat the neovascular form of age-related macular degeneration (wet AMD). Regeneron's submission includes a request for priority PDUFA review.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.